These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32187210)

  • 1. Opportunistic screening for type 2 diabetes in community pharmacies. Results from a region-wide experience in Italy.
    Gnavi R; Sciannameo V; Baratta F; Scarinzi C; Parente M; Mana M; Giaccone M; Cavallo Perin P; Costa G; Spadea T; Brusa P
    PLoS One; 2020; 15(3):e0229842. PubMed ID: 32187210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment and HbA1c measurement in Norwegian community pharmacies to identify people with undiagnosed type 2 diabetes - A feasibility study.
    Risøy AJ; Kjome RLS; Sandberg S; Sølvik UØ
    PLoS One; 2018; 13(2):e0191316. PubMed ID: 29474501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating FINDRISC as a screening tool for type 2 diabetes among overweight adults in the PREVIEW:NZ cohort.
    Silvestre MP; Jiang Y; Volkova K; Chisholm H; Lee W; Poppitt SD
    Prim Care Diabetes; 2017 Dec; 11(6):561-569. PubMed ID: 28801192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting persons at risk for diabetes mellitus type 2 using FINDRISC: results from a community pharmacy-based study.
    Milovanovic S; Silenzi A; Kheiraoui F; Ventriglia G; Boccia S; Poscia A
    Eur J Public Health; 2018 Dec; 28(6):1127-1132. PubMed ID: 29408980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of community pharmacy-based services for type-2 diabetes in an Indonesian setting: pharmacist survey.
    Wibowo Y; Parsons R; Sunderland B; Hughes J
    Int J Clin Pharm; 2015 Oct; 37(5):873-82. PubMed ID: 25986291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential screening for diabetes--evaluation of a campaign in Swiss community pharmacies.
    Hersberger KE; Botomino A; Mancini M; Bruppacher R
    Pharm World Sci; 2006 Jun; 28(3):171-9. PubMed ID: 17004016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes care in Norwegian pharmacies: a descriptive study.
    Kjome RL; Sandberg S; Granås AG
    Pharm World Sci; 2008 Apr; 30(2):191-8. PubMed ID: 17891470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two methods for assessing diabetes risk in a pharmacy setting in Australia.
    Kilkenny MF; Johnson R; Andrew NE; Purvis T; Hicks A; Colagiuri S; Cadilhac DA
    BMC Public Health; 2014 Nov; 14():1227. PubMed ID: 25427845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a collaborative diabetes screening campaign between community pharmacies and general practitioners.
    Murteira R; Cary M; Galante H; Romano S; Guerreiro JP; Rodrigues AT
    Prim Care Diabetes; 2023 Aug; 17(4):314-320. PubMed ID: 37156696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of the Finnish Diabetes Risk Score and a Simplified Finnish Diabetes Risk Score in a Community-Based, Cross-Sectional Programme for Screening of Undiagnosed Type 2 Diabetes Mellitus and Dysglycaemia in Madrid, Spain: The SPREDIA-2 Study.
    Salinero-Fort MA; Burgos-Lunar C; Lahoz C; Mostaza JM; Abánades-Herranz JC; Laguna-Cuesta F; Estirado-de Cabo E; García-Iglesias F; González-Alegre T; Fernández-Puntero B; Montesano-Sánchez L; Vicent-López D; Cornejo-Del Río V; Fernández-García PJ; Sánchez-Arroyo V; Sabín-Rodríguez C; López-López S; Patrón-Barandio P; Gómez-Campelo P;
    PLoS One; 2016; 11(7):e0158489. PubMed ID: 27441722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of people at risk of diabetes in community pharmacies of Pontevedra (Spain) (DEDIPO).
    Fornos-Pérez JA; Andrés-Rodríguez NF; Andrés-Iglesias JC; Luna-Cano R; García-Soidán J; Lorenzo-Veiga B; Mera-Gallego R; García-Riestra R
    Endocrinol Nutr; 2016 Oct; 63(8):387-96. PubMed ID: 27481442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacy diabetes screening trial (PDST): Outcomes of a national clustered RCT comparing three screening methods for undiagnosed type 2 diabetes (T2DM) in community pharmacy.
    Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Mc Namara KP
    Diabetes Res Clin Pract; 2023 Mar; 197():110566. PubMed ID: 36738834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity of the FINDRISC as a prediction tool for diabetes in a contemporary Norwegian population: a 10-year follow-up of the HUNT study.
    Jølle A; Midthjell K; Holmen J; Carlsen SM; Tuomilehto J; Bjørngaard JH; Åsvold BO
    BMJ Open Diabetes Res Care; 2019; 7(1):e000769. PubMed ID: 31803483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the Activities of Community Pharmacies during the Annual Campaign with Focus on Diabetes Prevention].
    Schmiedel K; Friedland K; Schlager H
    Gesundheitswesen; 2016 Oct; 78(10):678-680. PubMed ID: 26551848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of a novel pharmacy screening intervention to address the burden of type 2 diabetes and cardiovascular disease in an Arabic-speaking country.
    Alzubaidi H; Hasan S; Saidawi W; Mc Namara K; Chandir S; Krass I
    Diabet Med; 2021 Aug; 38(8):e14598. PubMed ID: 33969536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for type 2 diabetes mellitus in overweight and obese subjects made easy by the FINDRISC score.
    Meijnikman AS; De Block CE; Verrijken A; Mertens I; Corthouts B; Van Gaal LF
    J Diabetes Complications; 2016 Aug; 30(6):1043-9. PubMed ID: 27217020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection of type 2 diabetes in socioeconomically disadvantaged areas in Stockholm - comparing reach of community and facility-based screening.
    Timm L; Harcke K; Karlsson I; Sidney Annerstedt K; Alvesson HM; Stattin NS; Forsberg BC; Östenson CG; Daivadanam M
    Glob Health Action; 2020 Dec; 13(1):1795439. PubMed ID: 32746747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of a screening protocol for type 2 diabetes in community pharmacy. The DiabNow Study.
    Fikri-Benbrahim N; Martínez-Martínez F; Saéz-Benito L; Luque BS; Corpas JP; Moullin JC; Sabater-Hernández D
    Diabetes Res Clin Pract; 2015 Jun; 108(3):e49-52. PubMed ID: 25819481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk screening program in Australian community pharmacies.
    Peterson GM; Fitzmaurice KD; Kruup H; Jackson SL; Rasiah RL
    Pharm World Sci; 2010 Jun; 32(3):373-80. PubMed ID: 20217476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involving the public and other stakeholders in development and evaluation of a community pharmacy alcohol screening and brief advice service.
    Krska J; Mackridge AJ
    Public Health; 2014 Apr; 128(4):309-16. PubMed ID: 24713598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.